© 2017 Evestra, Inc.

2018

Conferences

April

AACR annual meeting; Chicago, USA

Poster: “Development of LIFR inhibitor EC359 as a novel therapeutic for ovarian cancer” Viswanadhapalli S., Nair H.B., Santhamma S., Sareddy G.R., Pan X., Edward K.R., Murali R., Tekmal R.R., Nickisch K., Vadlamudi R.K.

March

Gynecological Endocrinology - 18th World Congress; Firenze, Italy

Poster: “EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human fibroid tissue xenograft model” Nickisch K., Santhamma B., Schenken R., Binkley P., Nair H.B.

Poster: “Contributions to Ulipristals mechanism of action as Emergency Contraceptive Agent” Elger W., Nickisch K.

2017

 

October

12th Congress of European Society of Gynecology; Barcelona, Spain

Poster: “Orientating studies aimed at an animal model for the study of hormonal emergency contraception (HEC)“ Nickisch K., Elger W., Schneider B., Friedrich M.

 

EORTC-NCI-AACR meeting; Philadelphia, USA

Poster: “Development of a first-in-class leukemia inhibitory factor (LIF)/LIFR, EC359 for targeted therapy” Nair H.B., Santhamma B., Viswanadhapalli S., Sareddy G.R., Pan X., Vadlamudi R.K., Ramachandran M., Nickisch K.

April

AACR Annual Meeting; Washington DC, USA

Poster: “Development of cell line derived organoids to evaluate stroma targeted therapies in pancreatic cancerHall B., Santhamma B., Cannon A., Bhatia R., Kumar S., Are C., Nair H.B., Nickisch K., Batra S.

2016

 

November

EORTC-NCI-AACR meeting; Berlin, Germany

Poster: “Discovery and preclinical pharmacology of EC330: A First-in-class leukemia inhibitory factor (LIF) inhibitor” Nair H.B., Santhamma B., Viswanadhapalli S., Sareddy S.R., Manthati V., Vadlamudi R.K., Nickisch K.

April

AACR annual meeting; New Orleans, USA

Poster: “First in class steroidal Leukemia Inhibitory Factor (LIF) inhibitor in targeted cancer therapy” Nair H.B., Santhamma B., Viswanadhapalli S., Nickisch K.

2014

 

December

AACR-San Antonio Breast Cancer Symposium; San Antonio TX, USA

Poster: „Effect of a novel selective progesterone receptor modulator EC312 for menopausal hormone therapy (MHT) in comparison with Bazedoxifene in vitroNair H.B., Santhamma B., Elger W., Nickisch K.

2012

 

December

AACR-San Antonio Breast Cancer Symposium; San Antonio TX, USA

Poster: “EC 304: A Novel Progesterone Receptor (PR) Antagonist Inhibits Transcription and Induce Cell Cycle Arrest in T47D Breast Cancer Cells” Bhaskaran S., Kesavaram N., Nickisch K., Nair H.B.